N

NeuBase Therapeutics Inc
F:O7PA

Watchlist Manager
NeuBase Therapeutics Inc
F:O7PA
Watchlist
Price: 0.159 EUR -3.64%
Market Cap: €5.4m

NeuBase Therapeutics Inc
Other Items

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

NeuBase Therapeutics Inc
Other Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Items CAGR 3Y CAGR 5Y CAGR 10Y
N
NeuBase Therapeutics Inc
F:O7PA
Other Items
$10k
CAGR 3-Years
N/A
CAGR 5-Years
-55%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Other Items
-$5.9B
CAGR 3-Years
-108%
CAGR 5-Years
31%
CAGR 10-Years
4%
Gilead Sciences Inc
NASDAQ:GILD
Other Items
-$3B
CAGR 3-Years
-22%
CAGR 5-Years
8%
CAGR 10-Years
11%
Amgen Inc
NASDAQ:AMGN
Other Items
-$1.3B
CAGR 3-Years
13%
CAGR 5-Years
33%
CAGR 10-Years
11%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other Items
-$1.1B
CAGR 3-Years
-40%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other Items
$691.2m
CAGR 3-Years
N/A
CAGR 5-Years
2%
CAGR 10-Years
N/A
No Stocks Found

NeuBase Therapeutics Inc
Glance View

Market Cap
5.4m EUR
Industry
Biotechnology

NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 33 full-time employees. The firm is focused on developing therapies to treat rare genetic diseases and cancers caused by mutant genes. The Company’s peptide-nucleic acid antisense oligonucleotide (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders. Its programs include NT0100, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the HD messenger ribonucleic acid (mRNA) and NT0200, a PATrOL-enabled therapeutic program for systemic administration to target the mutant expansion in the myotonic dystrophy type one disease mRNA.

O7PA Intrinsic Value
Not Available

See Also

What is NeuBase Therapeutics Inc's Other Items?
Other Items
10k USD

Based on the financial report for Sep 30, 2023, NeuBase Therapeutics Inc's Other Items amounts to 10k USD.

What is NeuBase Therapeutics Inc's Other Items growth rate?
Other Items CAGR 5Y
-55%

Back to Top